Electromed, Inc.: insider trades · United States · SEC (Form 4)

About Electromed, Inc.

Electromed, Inc. (ticker: ELMD) is a U.S.-listed medical device company traded on NYSE American in the United States, with a focused small- to mid-cap profile. Headquartered in New Prague, Minnesota, and founded in 1992, the company has built its business around airway clearance therapy for patients with compromised pulmonary function. Electromed develops, manufactures, markets, and supports products based on High Frequency Chest Wall Oscillation (HFCWO), a therapy designed to help mobilize and clear mucus from the airways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000089710124000486/elmd241000_ars.pdf?utm_source=openai)) Its core commercial platform is the SmartVest franchise, including the latest SmartVest Clearway system, the earlier SmartVest SQL, and related garments and accessories. These products are used in conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular or chronic respiratory disorders. Importantly, Electromed is not just a device vendor: it operates a service-heavy model that includes patient and clinician education, therapy training, follow-up support, reimbursement assistance, and ongoing engagement to help integrate therapy into daily care. That service layer is strategically important in a niche market where reimbursement, adherence, and clinical support heavily influence adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034445/elmd20250930_10q.htm?utm_source=openai)) From a competitive standpoint, Electromed is a specialist rather than a diversified medtech conglomerate. Management consistently frames the company as a leader in the airway clearance category, supported by clinical outcomes data, established reimbursement pathways, and a direct-to-patient/provider go-to-market approach. The business is overwhelmingly U.S.-centric: most revenue is generated domestically, while international sales remain modest. Manufacturing is also based in Minnesota, which suggests a relatively integrated operating model and tighter control over product quality and supply chain execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001488917/000143774926016422/ex_920786.htm?utm_source=openai)) Recent company communications highlight continued growth, profitability, and commercial investment. Management has emphasized salesforce expansion, CRM and capital spending, market-development initiatives, and share repurchases, while investor presentations have continued to position the company as a growing and profitable medical technology business. For investors tracking SEC Form 4 insider activity, ELMD is also notable because insider transactions are followed closely and may reflect compensation-related grants, routine selling, or broader management alignment. Overall, Electromed remains a niche healthcare name with a clear respiratory-care focus, where execution on commercialization, reimbursement, and the expansion of home-based airway clearance demand are the key investment drivers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034438/ex_859448.htm?utm_source=openai))